MRNA vs ROST

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

MRNA

35.2
AI Score
VS
ROST Wins

ROST

54.5
AI Score

Investment Advisor Scores

MRNA

35score
Recommendation
SELL

ROST

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA ROST Winner
Revenue 534.00M 12.28B ROST
Net Income -2.13B 1.50B ROST
Net Margin -397.9% 12.2% ROST
Operating Income -2.20B 1.91B ROST
ROE -31.4% 22.3% ROST
ROA -19.4% 9.4% ROST
Total Assets 10.96B 15.98B ROST
Cash 1.72B 4.29B ROST
Debt/Equity 0.09 0.15 MRNA
Current Ratio 2.29 1.61 MRNA
Free Cash Flow -1.25B 1.25B ROST

Relative Price Performance (Last 90 Days)

MRNA 1M: +25.5% · 3M: +131.5% ROST 1M: -0.9% · 3M: +8.3%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (47.6% over 20 days), RSI 66

RSI (14): 66.0 · Price: $189.33

ROST

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 43.7 · Price: $228.84

Fundamentals Snapshot

Metric MRNA ROST
Market Cap — —
Forward P/E -39.7 31.7
Trailing P/E — 28.2
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.3%
Operating Margin -5.6% 0.1%
EPS -7.82 8.29
Dividend Yield — 0.01%

Frequently Asked Questions

Based on our detailed analysis, ROST is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.